Germline PTPN13 mutations in patients with bone marrow failure and acute lymphoblastic leukemia

Moshiri, Houtan; Riofrío, David A. Cabrera; Lim, Yeon Jung; Lauhasurayotin, Supanun; Manisterski, Michal; Elhasid, Ronit; Bonilla, Francisco A.; Dhanraj, Santhosh; Armstrong, Richard N.; Li, Hongbing; Scherer, Stephen W.; Hernández‐Hernández, Ángel; Dror, Yigal

doi:10.1038/s41375-022-01610-4

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Roles for PTPN13 in both promoting and suppressing tumour development have been reported (reviewed in [105]). Thus, PTPN13 may suppress oncogenic Src signalling [106], whilst the loss of PTPN13 expression [107] or germ-line mutations in PTPN13 [108] have been described in NSCLC and acute lymphoblastic leukaemia, respectively. PTPN13 has been described as a STAT phosphatase and regulates CD4 + T helper cell differentiation in mice [109].…”

Section: Ptpn3 Ptpn4 and Ptpn13mentioning

confidence: 99%

Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies

Salmond

2024

Cells

View full text Add to dashboard Cite

Advances in immunotherapy have brought significant therapeutic benefits to many cancer patients. Nonetheless, many cancer types are refractory to current immunotherapeutic approaches, meaning that further targets are required to increase the number of patients who benefit from these technologies. Protein tyrosine phosphatases (PTPs) have long been recognised to play a vital role in the regulation of cancer cell biology and the immune response. In this review, we summarize the evidence for both the pro-tumorigenic and tumour-suppressor function of non-receptor PTPs in cancer cells and discuss recent data showing that several of these enzymes act as intracellular immune checkpoints that suppress effective tumour immunity. We highlight new data showing that the deletion of inhibitory PTPs is a rational approach to improve the outcomes of adoptive T cell-based cancer immunotherapies and describe recent progress in the development of PTP inhibitors as anti-cancer drugs.

show abstract

Section: Ptpn3 Ptpn4 and Ptpn13mentioning

confidence: 99%

Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies

Salmond

2024

Cells

View full text Add to dashboard Cite

show abstract

“…Until now, the clinical function and molecular mechanism of PTPN13 in BRCA remains largely unidentified [14]. In addition, PTPN13 variation and its consequences in BRCA have not yet been reported [15]. Therefore, given the higher tumor mutational burden (TMB) of TNBC [16], we retrospectively enrolled 14 locally advanced TNBC patients with residual cancer burden (RCB) tissues after neoadjuvant chemotherapy (NAC).…”

mentioning

confidence: 99%